[go: up one dir, main page]

MX2016014564A - Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido. - Google Patents

Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.

Info

Publication number
MX2016014564A
MX2016014564A MX2016014564A MX2016014564A MX2016014564A MX 2016014564 A MX2016014564 A MX 2016014564A MX 2016014564 A MX2016014564 A MX 2016014564A MX 2016014564 A MX2016014564 A MX 2016014564A MX 2016014564 A MX2016014564 A MX 2016014564A
Authority
MX
Mexico
Prior art keywords
lipopolisacarido
lent
vaccine against
acinetobacter
polishing components
Prior art date
Application number
MX2016014564A
Other languages
English (en)
Other versions
MX375274B (es
Inventor
James Mcconnell Michael
GARCÍA QUINTANILLA Meritxell
Pulido Toledano Marina
Pilar Pérez-Romero María
Pachón Díaz Jerónimo
José INFANTE VIÑOLO Juan
Original Assignee
Vaxdyn Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxdyn Sl filed Critical Vaxdyn Sl
Publication of MX2016014564A publication Critical patent/MX2016014564A/es
Publication of MX375274B publication Critical patent/MX375274B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a una composición que comprende células inactivadas carentes de LPS del género Acinetobacter y/o vesículas de membrana externa de las mismas y a su uso para la fabricación de un medicamento, preferiblemente una vacuna, para la prevención de enfermedades producidas por organismos del género Acinetobacter.
MX2016014564A 2014-05-05 2015-05-05 Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido. MX375274B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382164.3A EP2942389A1 (en) 2014-05-05 2014-05-05 Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
PCT/EP2015/059870 WO2015169809A1 (en) 2014-05-05 2015-05-05 Vaccine against acinetobacter baumannii based on cellular components deficient in lipopolysaccharide

Publications (2)

Publication Number Publication Date
MX2016014564A true MX2016014564A (es) 2017-05-30
MX375274B MX375274B (es) 2025-03-06

Family

ID=51059396

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014564A MX375274B (es) 2014-05-05 2015-05-05 Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.

Country Status (9)

Country Link
US (3) US20170065700A1 (es)
EP (2) EP2942389A1 (es)
JP (1) JP6775424B2 (es)
CN (1) CN107073095B (es)
DK (1) DK3140391T3 (es)
ES (1) ES2848066T3 (es)
MX (1) MX375274B (es)
PT (1) PT3140391T (es)
WO (1) WO2015169809A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942389A1 (en) 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
US11291712B2 (en) 2017-09-20 2022-04-05 The United States Government As Represented By The Department Of Veterans Affairs Bacterial protein compositions and uses thereof
KR102902731B1 (ko) * 2018-04-10 2025-12-22 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 애주번트로서의 버크홀데리아 슈도말레이 복합체 외막 소포체
US11819532B2 (en) * 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
CN110283745B (zh) * 2019-06-27 2021-05-11 浙江工业大学 医院不动杆菌fk2及其在降解有机污染物中的应用
CN110746496B (zh) * 2019-09-30 2023-07-07 四川大学华西医院 一种鲍曼不动杆菌的pal重组蛋白及其编码基因和它们的应用
WO2022140382A1 (en) * 2020-12-22 2022-06-30 Biological Mimetics, Inc. Irradiated whole-cell immunogens of acinetobacter baumannii
EP4281538A4 (en) * 2021-01-25 2024-11-20 Avails Medical, Inc. APPARATUS, SYSTEMS AND METHODS FOR PREPARING AN OUTPUT SAMPLE HAVING AERATION
CN113234625B (zh) * 2021-05-08 2022-05-24 哈尔滨师范大学 一株皮特不动杆菌及其应用
EP4169529A1 (en) 2021-10-20 2023-04-26 Vaxdyn S.L. Lipopolysaccharide (lps) deficient acinetobacter baumannii multivalent vaccine
CN116855475B (zh) * 2023-05-08 2025-12-23 中国农业科学院农产品加工研究所 脱毒酶Novel porin及其制备方法和应用
CN116478953B (zh) * 2023-06-14 2023-09-12 四川大学华西医院 鲍曼不动杆菌DlaT重组蛋白、制备方法及应用
CN116462743B (zh) * 2023-06-14 2023-09-19 四川大学华西医院 鲍曼不动杆菌翻译延伸因子重组蛋白、制备方法及应用
CN117603319B (zh) * 2023-11-21 2025-08-15 南京市江宁医院 鲍曼不动杆菌多抗原表位多肽rOmpW及其应用
CN118178352A (zh) * 2024-04-10 2024-06-14 广东云曌医疗科技有限公司 一种抗菌药物纳米材料及其制备方法和应用
CN118978577B (zh) * 2024-10-22 2025-03-11 四川大学华西医院 鲍曼不动杆菌ba71_01558重组蛋白抗原、制备方法及其应用
CN119709810A (zh) * 2024-11-03 2025-03-28 浙江大学 鲍曼不动杆菌荚膜相关基因敲除的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101575587B (zh) * 2009-06-03 2011-01-05 中国农业大学 一种流产布鲁氏菌重组菌及其在制备疫苗中的应用
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
BR112014005773A2 (pt) * 2011-09-14 2019-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center composições derivadas de hyr1 e métodos of tratamento usando as mesmas
WO2014048976A1 (en) * 2012-09-25 2014-04-03 Vaxdyn Sl Anti-acinetobacter baumannii immunogens
CN102977208B (zh) * 2012-12-12 2015-04-08 大连医科大学 鲍曼不动杆菌特异性卵黄免疫球蛋白的制备方法、应用及药物组合物、制剂和试剂盒
EP2942389A1 (en) 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components

Also Published As

Publication number Publication date
JP6775424B2 (ja) 2020-10-28
CN107073095B (zh) 2022-04-19
US20220152184A1 (en) 2022-05-19
US20180256700A1 (en) 2018-09-13
CN107073095A (zh) 2017-08-18
EP2942389A1 (en) 2015-11-11
US20170065700A1 (en) 2017-03-09
MX375274B (es) 2025-03-06
JP2017514873A (ja) 2017-06-08
PT3140391T (pt) 2021-01-06
DK3140391T3 (da) 2021-01-11
EP3140391A1 (en) 2017-03-15
ES2848066T3 (es) 2021-08-05
US11160856B2 (en) 2021-11-02
EP3140391B1 (en) 2020-10-07
WO2015169809A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
MX2016014564A (es) Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
MX2017000569A (es) Emulsiones de silicona.
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
ECSP14007644A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
MX378904B (es) Vacunas para virus influenza y usos de las mismas.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX2018002318A (es) Proceso mejorado para producir fucoxantina y/o polisacaridos de microalgas.
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.

Legal Events

Date Code Title Description
FG Grant or registration